drugset
drugset / Trial / NCT04769479

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

NCT04769479 ↗

Phase 1 Completed 14 enrolled Eidos Therapeutics, a BridgeBio company
NaSingle-groupOpen-labelTreatment

Summary

This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.

Timeline

Start
2021-03-28
Primary completion
2021-08-04
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acoramidis Unknown — —

Indications

amyloidosis